Physician profile
Shuping Wang
NPI 1215043377
$3,358.18
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $596 · 2020: $400 · 2021: $286 · 2022: $985 · 2023: $836 · 2024: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $984 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $983.99 |
| Education | $106.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $565.67 | 2019-2024 | Farxiga |
| Mallinckrodt Hospital Products INC. | $551.12 | 2020-2024 | Acthar |
| Otsuka America Pharmaceutical, INC. | $399.04 | 2019-2024 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $208.33 | 2022-2024 | |
| Mallinckrodt Enterprises LLC | $207.77 | 2019 | |
| Akebia Therapeutics INC | $187.14 | 2019-2024 | Auryxia |
| Vifor Pharma, INC. | $156.99 | 2019-2023 | Veltassa |
| Opko Pharmaceuticals, LLC | $141.08 | 2019-2024 | Rayaldee |
| Amgen INC. | $108.70 | 2019-2022 | |
| Travere Therapeutics, INC. | $101.83 | 2022-2024 | |
| Horizon Therapeutics Plc | $95.87 | 2021-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $94.02 | 2022-2023 | Tarpeyo |
| Fresenius USA Marketing, INC. | $92.99 | 2019-2021 | |
| Glaxosmithkline, LLC. | $89.52 | 2022-2023 | Benlysta |
| Baxter Healthcare | $60.00 | 2019-2023 | Renal - Extraneal Solution |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $58.26 | 2022 | |
| Ani Pharmaceuticals, INC. | $54.52 | 2022 | |
| Aurinia Pharma U.S., INC. | $50.12 | 2022-2023 | Lupkynis |
| Ardelyx, INC. | $47.15 | 2024 | Ibsrela |
| Lilly USA, LLC | $24.97 | 2024 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $22.96 | 2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $22.46 | 2022 | |
| Kyowa Kirin, INC. | $17.67 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shuping Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.